These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 31214500)

  • 1. Dynamics of Minimal Residual Disease in Neuroblastoma Patients.
    Uemura S; Ishida T; Thwin KKM; Yamamoto N; Tamura A; Kishimoto K; Hasegawa D; Kosaka Y; Nino N; Lin KS; Takafuji S; Mori T; Iijima K; Nishimura N
    Front Oncol; 2019; 9():455. PubMed ID: 31214500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Minimal residual disease in high-risk neuroblastoma shows a dynamic and disease burden-dependent correlation between bone marrow and peripheral blood.
    Lin KS; Uemura S; Thwin KKM; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
    Transl Oncol; 2021 Aug; 14(8):101019. PubMed ID: 33993097
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse.
    Loh AHP; Angelina C; Wong MK; Tan SH; Sukhatme SA; Yeo T; Lim SB; Lee YT; Soh SY; Leung W; Chang KTE; Chua YW; Alkaff SMF; Lim TKH; Lim CT; Chen ZX
    Front Oncol; 2022; 12():939460. PubMed ID: 36176417
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Differential expression of minimal residual disease markers in peripheral blood and bone marrow samples from high-risk neuroblastoma patients.
    Yamamoto N; Kozaki A; Hartomo TB; Yanai T; Hasegawa D; Kawasaki K; Kosaka Y; Matsuo M; Hirase S; Mori T; Hayakawa A; Iijima K; Nishio H; Nishimura N
    Oncol Lett; 2015 Nov; 10(5):3228-3232. PubMed ID: 26722317
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Higher levels of minimal residual disease in peripheral blood than bone marrow before 1st and 2nd relapse/regrowth in a patient with high‑risk neuroblastoma: A case report.
    Inoue S; Win KHN; Mon CY; Fujikawa T; Hyodo S; Uemura S; Ishida T; Mori T; Hasegawa D; Kosaka Y; Nishimura A; Nakatani N; Nino N; Tamura A; Yamamoto N; Nozu K; Nishimura N
    Oncol Lett; 2023 Sep; 26(3):369. PubMed ID: 37559575
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Minimal residual disease monitoring in neuroblastoma patients based on the expression of a set of real-time RT-PCR markers in tumor-initiating cells.
    Hartomo TB; Kozaki A; Hasegawa D; Van Huyen Pham T; Yamamoto N; Saitoh A; Ishida T; Kawasaki K; Kosaka Y; Ohashi H; Yamamoto T; Morikawa S; Hirase S; Kubokawa I; Mori T; Yanai T; Hayakawa A; Takeshima Y; Iijima K; Matsuo M; Nishio H; Nishimura N
    Oncol Rep; 2013 Apr; 29(4):1629-36. PubMed ID: 23417100
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Limited correlation between tumor markers and minimal residual disease detected by seven neuroblastoma-associated mRNAs in high-risk neuroblastoma patients.
    Uemura S; Lin KS; Mon Thwin KK; Nakatani N; Ishida T; Yamamoto N; Tamura A; Saito A; Mori T; Hasegawa D; Kosaka Y; Nino N; Nagano C; Takafuji S; Iijima K; Nishimura N
    Mol Clin Oncol; 2021 Jul; 15(1):137. PubMed ID: 34055352
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal Residual Disease Detected by the 7NB-mRNAs ddPCR Assay Is Associated with Disease Progression in High-Risk Neuroblastoma Patients: A Prospective Multicenter Observational Study in Japan.
    Nishimura N; Ishida T; Yokota I; Matsumoto K; Shichino H; Fujisaki H; Sarashina T; Kamijo T; Takimoto T; Iehara T; Tajiri T; On Behalf Of The Jccg Neuroblastoma Committee
    Biology (Basel); 2023 Oct; 12(10):. PubMed ID: 37887060
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Minimal residual disease levels in bone marrow and peripheral blood are comparable in children with T cell acute lymphoblastic leukemia (ALL), but not in precursor-B-ALL.
    van der Velden VH; Jacobs DC; Wijkhuijs AJ; Comans-Bitter WM; Willemse MJ; Hählen K; Kamps WA; van Wering ER; van Dongen JJ
    Leukemia; 2002 Aug; 16(8):1432-6. PubMed ID: 12145681
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective monitoring of minimal residual disease during the course of chemotherapy in patients with acute lymphoblastic leukemia, and detection of contaminating tumor cells in peripheral blood stem cells for autotransplantation.
    Seriu T; Yokota S; Nakao M; Misawa S; Takaue Y; Koizumi S; Kawai S; Fujimoto T
    Leukemia; 1995 Apr; 9(4):615-23. PubMed ID: 7723394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Peripheral blood minimal residual disease may replace bone marrow minimal residual disease as an immunophenotypic biomarker for impending relapse in acute myeloid leukemia.
    Zeijlemaker W; Kelder A; Oussoren-Brockhoff YJ; Scholten WJ; Snel AN; Veldhuizen D; Cloos J; Ossenkoppele GJ; Schuurhuis GJ
    Leukemia; 2016 Mar; 30(3):708-15. PubMed ID: 26373238
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Detecting liquid remnants of solid tumors treated with curative intent: Circulating tumor DNA as a biomarker of minimal residual disease (Review).
    Chen H; Zhou Q
    Oncol Rep; 2023 May; 49(5):. PubMed ID: 37052271
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monitoring of minimal residual disease in adult acute myeloid leukemia using peripheral blood as an alternative source to bone marrow.
    Maurillo L; Buccisano F; Spagnoli A; Del Poeta G; Panetta P; Neri B; Del Principe MI; Mazzone C; Consalvo MI; Tamburini A; Ottaviani L; Fraboni D; Sarlo C; De Fabritiis P; Amadori S; Venditti A
    Haematologica; 2007 May; 92(5):605-11. PubMed ID: 17488683
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DTCs in breast cancer: clinical research and practice.
    Janni W; Rack B; Kasprowicz N; Scholz C; Hepp P
    Recent Results Cancer Res; 2012; 195():173-8. PubMed ID: 22527504
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detecting minimal residual disease in neuroblastoma: the superiority of a panel of real-time quantitative PCR markers.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Yalcin B; Dee R; van Noesel MM; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    Clin Chem; 2009 Jul; 55(7):1316-26. PubMed ID: 19460840
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma.
    Stutterheim J; Gerritsen A; Zappeij-Kannegieter L; Kleijn I; Dee R; Hooft L; van Noesel MM; Bierings M; Berthold F; Versteeg R; Caron HN; van der Schoot CE; Tytgat GA
    J Clin Oncol; 2008 Nov; 26(33):5443-9. PubMed ID: 18838715
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of FOLFOX on minimal residual disease in Stage III colon cancer and risk of relapse.
    Murray NP; Aedo S; Villalon R; López MA; Minzer S; Muñoz L; Orrego S; Contreras L; Arzeno L; Guzman E
    Ecancermedicalscience; 2019; 13():935. PubMed ID: 31281432
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating Tumor DNA and Minimal Residual Disease (MRD) in Solid Tumors: Current Horizons and Future Perspectives.
    Peng Y; Mei W; Ma K; Zeng C
    Front Oncol; 2021; 11():763790. PubMed ID: 34868984
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of Circulating and Disseminated Neuroblastoma Cells Using the ImageStream Flow Cytometer for Use as Predictive and Pharmacodynamic Biomarkers.
    Merugu S; Chen L; Gavens E; Gabra H; Brougham M; Makin G; Ng A; Murphy D; Gabriel AS; Robinson ML; Wright JH; Burchill SA; Humphreys A; Bown N; Jamieson D; Tweddle DA
    Clin Cancer Res; 2020 Jan; 26(1):122-134. PubMed ID: 31767563
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flow-cytometric minimal residual disease monitoring in blood predicts relapse risk in pediatric B-cell precursor acute lymphoblastic leukemia in trial AIEOP-BFM-ALL 2000.
    Schumich A; Maurer-Granofszky M; Attarbaschi A; Pötschger U; Buldini B; Gaipa G; Karawajew L; Printz D; Ratei R; Conter V; Schrappe M; Mann G; Basso G; Dworzak MN;
    Pediatr Blood Cancer; 2019 May; 66(5):e27590. PubMed ID: 30561169
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.